Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

September 30, September 30, 2008 2007 2008 2007 Total revenues $23,330 $29,467 $77,791 $66,067 Costs and expenses: Cost of product revenues 10,730 5,607 30,835 14,640 Research and development 7,097 12,433 24,964 41,927 Marketing, general and administrative 16,155 18,740 75,854 60,185 Acquired in-process research and development - - - 50,000 Amortization of intangibles 637 496 2,267 910 Restructuring Charge (549) - 2,980 - Total costs and expenses 34,070 37,276 136,900 167,662 Loss from operations (10,740) (7,809) (59,109) (101,595) Investment income 532 763 2,692 3,354 Interest expense (3,595) (1,614) (8,958) (5,492) Minority interest and other (175) (93) (175) (93) Net loss $(13,978) $(8,753) $(65,551) $(103,826) Net loss per common share: Basic and diluted $(0.18) $(0.12) $(0.86) $(1.61) Weighted average common shares: Basic and diluted 77,076 75,900 76,565 64,679 INDEVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) September 30, September 30, 2008 2007 Cash, cash equivalents $131,306 $71,142 Restricted cash 10,000 - Goodwill 48,244 48,244 Intangible assets,
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... of its 2015 fiscal year, which ended Aug. 31, ... income of $7,839,000 in the first quarter of last ... 30, 2013, earnings per share in the current quarter ... First quarter revenues increased 15% to $67,599,000, from ...
(Date:9/22/2014)... PRINCETON, N.J. , Sept. 22, 2014 /PRNewswire/ ... regulatory and ethical review services for clinical research, ... ® (WIRB) has been reaccredited by the ... Programs (AAHRPP), which endeavors to improve safeguards for ... CEO Donald A. Deieso , Ph.D., commented, ...
(Date:9/22/2014)... 22, 2014 METTLER TOLEDO is ... pallet measuring device CNS110 ScanTape™ . Replacing ... entry, offering greater ease and accuracy for transport ... can significantly enhance productivity—an important benefit for load ... volume equals profits. , Usable at any ...
(Date:9/22/2014)... Md. , Sept. 22, 2014  Spherix Incorporated (SPEX) ... and monetization of intellectual property, today announced that the United ... to the Company in the month of September that is ... The issued patent is: USRE45,121 , Application ... , Filing date: Dec 27, 2012 ...
Breaking Biology Technology:Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2ScanTape™ Handheld Dimensioner Increases Processing Volume 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3
... and PHILADELPHIA, July 4 ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), ... earnings on,Thursday 31 July 2008, Results press ... BST / 07:00 EDT Investor meeting and conference ... Investor & Analyst meeting and conference call:, Angus ...
... Research Group has,released results from aboratory testing ... at Oregon State University which,demonstrated the Eniva ... for human cells. This third party testing ... effort to further identify,mechanisms by which the ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today announced that ... its cash burn rate. As previously,announced, the Company ... acquisitions and mergers. In conjunction with this,process, the ... its VP,series of drugs, and has determined that ...
Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2Vasogen Provides Corporate Update 2
(Date:9/21/2014)... new strains of bacteria have emerged that resist even ... drug-resistant forms of tuberculosis and staphylococcus, infect more than ... Despite the urgent need for new treatments, scientists have ... past decade. , MIT engineers have now turned a ... system that can disable any target gene, they have ...
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... University of Oklahoma biology professor will study the unique ... that could eventually benefit people,s health. The OU ... the energy required to produce the signals used to ... electric signals at a rate of 500-600 discharges a ... for the electric fish are extreme, but necessary for ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) ... genetics of ALS. Amyotrophic lateral sclerosis (ALS), also ... fatal neurological disease involving the degeneration and death of ... the most common neuromuscular diseases worldwide, affecting as roughly ...
... sturgeons, more caviar will be exported from Caspian Sea ... of unacceptably permissive new trade quotas announced Thursday by ... Most sturgeon species are endangered and some, like beluga ... damage this ancient fish,s chance of recovery and survival, ...
... New research* shows that while engineered nanomaterials can ... food chain from single celled organisms to higher ... and there was no evidence of the nanomaterials ... results observed by researchers from the National Institute ...
Cached Biology News:New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4Research measures movement of nanomaterials in simple model food chain 2
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
... for use in the Microsart e.motion are sterile-sealed, ... in a specially designed individual package on a ... band of membrane filter units ensures that they ... the sealed band guarantees uniform dispensing of the ...
...
... Speed Rocker, with 12" x 14" table; 115V ... 14" table; 220V. The VSR-50 Variable Speed ... any lab. The VSR-50 provides a rhythmic side-to-side ... gentle to vigourous movement. This makes it ideal ...
Biology Products: